![Hans Louis Jos de Winter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loopbaan van Hans Louis Jos de Winter
Eerdere bekende functies van Hans Louis Jos de Winter
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Directeur/Bestuurslid | 10-05-2010 | 11-05-2012 |
Hoofd Techniek/Wetenschap/O&O | 01-01-2005 | 11-05-2012 | |
Oprichter | 01-01-2005 | 11-05-2012 | |
Victoria University | Corporate Officer/Principal | - | - |
The Janssen Research Foundation | Hoofd Techniek/Wetenschap/O&O | 01-01-1996 | - |
Opleiding van Hans Louis Jos de Winter
Université Catholique de Louvain | Undergraduate Degree |
Statistieken
Internationaal
België | 3 |
Verenigde Staten | 2 |
Australië | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Founder | 1 |
Sectoraal
Consumer Services | 3 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Silicos SA
![]() Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
The Janssen Research Foundation |